Role of citrate and other methods of anticoagulation in patients with severe liver failure requiring continuous renal replacement therapy

NDT Plus

Volumn 2, Issue 1, 2009, Pages 11-19

  Bouchard, Josée ^a   Madore, François ^a  

^a HÔPITAL DU SACRÉ COEUR DE MONTRÉAL   (Canada)

Author keywords

Anticoagulation; Citrate; Continuous renal replacement therapy; Liver failure

Indexed keywords

ARGATROBAN; BICARBONATE; CITRIC ACID; DALTEPARIN; DANAPAROID; ENOXAPARIN; HEPARIN; HIRUDIN; HIRULOG; LEPIRUDIN; LOW MOLECULAR WEIGHT HEPARIN; NADROPARIN; NAFAMSTAT MESILATE; PROSTACYCLIN; PROTAMINE; SODIUM CHLORIDE;

ALLERGIC REACTION; ANAPHYLAXIS; BLEEDING; BLEEDING TENDENCY; BRAIN EDEMA; BRAIN HEMORRHAGE; BRAIN PERFUSION; CLINICAL TRIAL; CONTINUOUS INFUSION; CONTINUOUS RENAL REPLACEMENT THERAPY; DRUG ANTAGONISM; DRUG EFFICACY; DRUG HALF LIFE; DRUG INHIBITION; DRUG SAFETY; DRUG WITHDRAWAL; GASTROINTESTINAL HEMORRHAGE; HUMAN; HYPOCALCEMIA; HYPOTENSION; HYPOXEMIA; INTERNATIONAL NORMALIZED RATIO; INTRACRANIAL PRESSURE; KIDNEY FAILURE; LIVER FAILURE; LIVER INJURY; METABOLIC ACIDOSIS; PORTAL VEIN THROMBOSIS; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; REVIEW; SIDE EFFECT; THROMBOCYTOPENIA;

EID: 58449124144     PISSN: 17530784     EISSN: 17530792     Source Type: Journal    
DOI: 10.1093/ndtplus/sfn184     Document Type: Review

References (82)

1. van de Wetering J, Westendorp RG, Van Der Hoeven JG et al. Heparin use in continuous renal replacement procedures: the struggle between filter coagulation and patient hemorrhage. J Am Soc Nephrol 1996; 7: 145-150
2. Grace ND. Prevention of initial variceal hemorrhage. Gastroenterol Clin North Am 1992; 21: 149-161
3. Violi F. How to concile bleeding and thrombotic tendency in liver cirrhosis? J Thromb Haemost 2006; 4: 2065-2066
4. Northup PG, Sundaram V, Fallon et al. Hypercoagulation and thrombophilia in liver disease. J Throm Haemost 2008; 6: 2-9
5. Senzolo M, Burra P, Cholongitas E et al. New insights into the coagulopathy of liver disease and liver transplantation. World J Gastroenterol 2006; 12: 7725-7736
6. Bakker CM, Knot EA, Stibbe J et al. Disseminated intravascular coagulation in liver cirrhosis. J Hepatol 1992; 15: 330-335
7. Langley PG, Forbes A, Hughes RD et al. Thrombin-antithrombin iii complex in fulminant hepatic failure: evidence for disseminated intravascular coagulation and relationship to outcome. Eur J Clin Invest 1990; 20: 627-631
8. Abramson S, Niles JL. Anticoagulation in continuous renal replacement therapy. Curr Opin Nephrol Hypertens 1999; 8: 701-707
9. Langley PG, Keays R, Hughes RD et al. Antithrombin iii supplementation reduces heparin requirement and platelet loss during hemodialysis of patients with fulminant hepatic failure. Hepatology 1991; 14: 251-256
10. Northup PG, McMahon MM, Ruhl AP et al. Coagulopathy does not fully protect hospitalized cirrhosis patients from peripheral venous thromboembolism. Am J Gastroenterol 2006; 101: 1524-1528; quiz 1680
11. Bastien O, French P, Paulus S et al. Antithrombin iii deficiency during continuous venovenous hemodialysis. Contrib Nephrol 1995; 116: 154-158
12. Kutsogiannis DJ, Gibney RT, Stollery D et al. Regional citrate versus systemic heparin anticoagulation for continuous renal replacement in critically ill patients. Kidney Int 2005; 67: 2361-2367
13. Tobe SW, Aujla P, Walele AA et al. A novel regional citrate anticoagulation protocol for CRRT using only commercially available solutions. J Crit Care 2003; 18: 121-129
14. Bellomo R, Teede H, Boyce N. Anticoagulant regimens in acute continuous hemodiafiltration: a comparative study. Intensive Care Med 1993; 19: 329-332
15. Uchino S, Fealy N, Baldwin I et al. Continuous venovenous hemofiltration without anticoagulation. ASAIO J 2004; 50: 76-80
16. Tan HK, Baldwin I, Bellomo R. Continuous veno-venous hemofiltration without anticoagulation in high-risk patients. Intensive Care Med 2000; 26: 1652-1657
17. Martin PY, Chevrolet JC, Suter P et al. Anticoagulation in patients treated by continuous venovenous hemofiltration: a retrospective study. Am J Kidney Dis 1994; 24: 806-812
18. Naka T, Wan L, Bellomo R et al. Kidney failure associated with liver transplantation or liver failure: the impact of continuous veno-venous hemofiltration. Int J Artif Organs 2004; 27: 949-955
19. Fiore G, Donadio PP, Gianferrari P et al. CVVH in postoperative care of liver transplantation. Minerva Anestesiol 1998; 64: 83-87
20. Amanzadeh J, Reilly RF, Jr. Anticoagulation and continuous renal replacement therapy. Semin Dial 2006; 19: 311-316
21. Uchino S, Fealy N, Baldwin I et al. Pre-dilution vs. post-dilution during continuous veno-venous hemofiltration: impact on filter life and azotemic control. Nephron Clin Pract 2003; 94: c94-c98
22. Van Der Voort PH, Gerritsen RT, Kuiper MA et al. Filter run time in CVVH: pre- versus post-dilution and nadroparin versus regional heparin-protamine anticoagulation. Blood Purif 2005; 23: 175-180
23. Ramesh Prasad GV, Palevsky PM, Burr R et al. Factors affecting system clotting in continuous renal replacement therapy: results of a randomized, controlled trial. Clin Nephrol 2000; 53: 55-60
24. Oudemans-van Straaten HM, Wester JP, de Pont AC et al. Anticoagulation strategies in continuous renal replacement therapy: can the choice be evidence based? Intensive Care Med 2006; 32: 188-202
25. Palsson R, Niles JL. Regional citrate anticoagulation in continuous venovenous hemofiltration in critically ill patients with a high risk of bleeding. Kidney Int 1999; 55: 1991-1997
26. Mehta RL, McDonald BR, Aguilar MM et al. Regional citrate anticoagulation for continuous arteriovenous hemodialysis in critically ill patients. Kidney Int 1990; 38: 976-981
27. Bagshaw SM, Laupland KB, Boiteau PJ et al. Is regional citrate superior to systemic heparin anticoagulation for continuous renal replacement therapy? A prospective observational study in an adult regional critical care system. J Crit Care 2005; 20: 155-161
28. Hetzel GR, Taskaya G, Sucker C et al. Citrate plasma levels in patients under regional anticoagulation in continuous venovenous hemofiltration. Am J Kidney Dis 2006; 48: 806-811
29. Swartz R, Pasko D, O'Toole J et al. Improving the delivery of continuous renal replacement therapy using regional citrate anticoagulation. Clin Nephrol 2004; 61: 134-143
30. Meier-Kriesche HU, Gitomer J, Finkel K et al. Increased total to ionized calcium ratio during continuous venovenous hemodialysis with regional citrate anticoagulation. Crit Care Med 2001; 29: 748-752
31. Scott VL, De Wolf AM, Kang Y et al. Ionized hypomagnesemia in patients undergoing orthotopic liver transplantation: a complication of citrate intoxication. Liver Transpl Surg 1996; 2: 343-347
32. Diaz J, Acosta F, Parrilla P et al. Serum ionized magnesium monitoring during orthotopic liver transplantation. Transplantation 1996; 61: 835-837
33. Morgera S, Haase M, Ruckert M et al. Regional citrate anticoagulation in continuous hemodialysis - acid-base and electrolyte balance at an increased dose of dialysis. Nephron Clin Pract 2005; 101: c211-c219
34. Gabutti L, Marone C, Colucci G et al. Citrate anticoagulation in continuous venovenous hemodiafiltration: a metabolic challenge. Intensive Care Med 2002; 28: 1419-1425
35. Monchi M, Berghmans D, Ledoux D et al. Citrate vs. Heparin for anticoagulation in continuous venovenous hemofiltration: a prospective randomized study. Intensive Care Med 2004; 30: 260-265
36. Betjes MG, van Oosterom D, van Agteren M et al. Regional citrate versus heparin anticoagulation during venovenous hemofiltration in patients at low risk for bleeding: similar hemofilter survival but significantly less bleeding. J Nephrol 2007; 20: 602-608
37. Morgera S, Scholle C, Voss G et al. Metabolic complications during regional citrate anticoagulation in continuous venovenous hemodialysis: single-center experience. Nephron Clin Pract 2004; 97: c131-c136
38. Van Der Voort PH, Postma SR, Kingma WP et al. Safety of citrate based hemofiltration in critically ill patients at high risk for bleeding: a comparison with nadroparin. Int J Artif Organs 2006; 29: 559-563
39. Balik M, Waldauf P, Plasil P et al. Prostacyclin versus citrate in continuous haemodiafiltration: an observational study in patients with high risk of bleeding. Blood Purif 2005; 23: 325-329
40. Meier-Kriesche HU, Finkel KW, Gitomer JJ et al. Unexpected severe hypocalcemia during continuous venovenous hemodialysis with regional citrate anticoagulation. Am J Kidney Dis 1999; 33: e8
41. Apsner R, Druml W. More on anticoagulation for continuous hemofiltration. N Engl J Med 1998; 338: 131-132
42. Kramer L, Bauer E, Joukhadar C et al. Citrate pharmacokinetics and metabolism in cirrhotic and noncirrhotic critically ill patients. Crit Care Med 2003; 31: 2450-2455
43. Kirschbaum B, Galishoff M, Reines HD. Lactic acidosis treated with continuous hemodiafiltration and regional citrate anticoagulation. Crit Care Med 1992; 20: 349-353
44. Palsson R, Laliberte KA, Niles JL. Choice of replacement solution and anticoagulant in continuous venovenous hemofiltration. Clin Nephrol 2006; 65: 34-42
45. Gong D, Ji D, Xu B et al. Regional citrate anticoagulation in critically ill patients during continuous blood purification. Chin Med J (Engl) 2003; 116: 360-363
46. Mehta RL, McDonald BR, Ward DM. Regional citrate anticoagulation for continuous arteriovenous hemodialysis. An update after 12 months. Contrib Nephrol 1991; 93: 210-214
47. Sanghvi SR, Becker B, Brunson A et al. Efficacy and safety of regional citrate anticoagulation in high flow CVVH (abstract). Blood Purif 2006; 24: 262
48. Sutaria S, Hoffert G, Fitzpatrick J, et al. Regional citrate anticoagulation for CVVHDF in patients with liver failure (abstract). Blood Purif 2005; 23: 166
49. Uchino S, Bellomo R, Morimatsu H et al. Continuous renal replacement therapy: a worldwide practice survey: the beginning and ending supportive therapy for the kidney (B.E.S.T. Kidney) investigators. Intensive Care Med 2007; 33: 1563-1570
50. Hirsh J, Raschke R. Heparin and low-molecular-weight heparin: the seventh ACCP conference on antithrombotic and thrombolytic therapy. Chest 2004; 126: 188S-203S
51. De Waele JJ, Van Cauwenberghe S, Hoste E et al. The use of the activated clotting time for monitoring heparin therapy in critically ill patients. Intensive Care Med 2003; 29: 325-328
52. Leslie GD, Jacobs IG, Clarke GM. Proximally delivered dilute heparin does not improve circuit life in continuous venovenous haemodiafiltration. Intensive Care Med 1996; 22: 1261-1264
53. Vargas Hein O, von Heymann C, Lipps M et al. Hirudin versus heparin for anticoagulation in continuous renal replacement therapy. Intensive Care Med 2001; 27: 673-679
54. Morabito S, Guzzo I, Solazzo A et al. Continuous renal replacement therapies: anticoagulation in the critically ill at high risk of bleeding. J Nephrol 2003; 16: 566-571
55. Biancofiore G, Esposito M, Bindi L et al. Regional filter heparinization for continuous veno-venous hemofiltration in liver transplant recipients. Minerva Anestesiol 2003; 69: 527-534 (in English) and 534-538 (in Italian)
56. Reeves JH, Cumming AR, Gallagher L et al. A controlled trial of low-molecular-weight heparin (dalteparin) versus unfractionated heparin as anticoagulant during continuous venovenous hemodialysis with filtration. Crit Care Med 1999; 27: 2224-2228
57. Joannidis M, Kountchev J, Rauchenzauner M et al. Enoxaparin vs. unfractionated heparin for anticoagulation during continuous venovenous hemofiltration: a randomized controlled crossover study. Intensive Care Med 2007; 33: 1571-1579
58. Langenecker SA, Felfernig M, Werba A et al. Anticoagulation with prostacyclin and heparin during continuous venovenous hemofiltration. Crit Care Med 1994; 22: 1774-1781
59. Davenport A, Will EJ, Davison AM. The effect of prostacyclin on intracranial pressure in patients with acute hepatic and renal failure. Clin Nephrol 1991; 35: 151-157
60. Davenport A, Will EJ, Davison AM. Adverse effects on cerebral perfusion of prostacyclin administered directly into patients with fulminant hepatic failure and acute renal failure. Nephron 1991; 59: 449-454
61. Davenport A, Will EJ, Davison AM. Comparison of the use of standard heparin and prostacyclin anticoagulation in spontaneous and pump-driven extracorporeal circuits in patients with combined acute renal and hepatic failure. Nephron 1994; 66: 431-437
62. Matsuo T, Kario K, Nakao K et al. Anticoagulation with nafamostat mesilate, a synthetic protease inhibitor, in hemodialysis patients with a bleeding risk. Haemostasis 1993; 23: 135-141
63. Inagaki O, Nishian Y, Iwaki R et al. Adsorption of nafamostat mesilate by hemodialysis membranes. Artif Organs 1992; 16: 553-558
64. Hu ZJ, Iwama H, Suzuki R et al. Time course of activated coagulation time at various sites during continuous haemodiafiltration using nafamostat mesilate. Intensive Care Med 1999; 25: 524-527
65. Davenport A. Anticoagulation options for patients with heparin-induced thrombocytopenia requiring renal support in the intensive care unit. Contrib Nephrol 2007; 156: 259-266
66. Levine RL, Hursting MJ, McCollum D. Argatroban therapy in heparin-induced thrombocytopenia with hepatic dysfunction. Chest 2006; 129: 1167-1175
67. Reddy BV, Grossman EJ, Trevino SA et al. Argatroban anticoagulation in patients with heparin-induced thrombocytopenia requiring renal replacement therapy. Ann Pharmacother 2005; 39: 1601-1605
68. Tang IY, Cox DS, Patel K et al. Argatroban and renal replacement therapy in patients with heparin-induced thrombocytopenia. Ann Pharmacother 2005; 39: 231-236
69. Dager WE, White RH. Argatroban for heparin-induced thrombocytopenia in hepato-renal failure and CVVHD. Ann Pharmacother 2003; 37: 1232-1236
70. Williamson DR, Boulanger I, Tardif M et al. Argatroban dosing in intensive care patients with acute renal failure and liver dysfunction. Pharmacotherapy 2004; 24: 409-414
71. Young G, Yonekawa KE, Nakagawa PA et al. Recombinant activated factor vii effectively reverses the anticoagulant effects of heparin, enoxaparin, fondaparinux, argatroban, and bivalirudin ex vivo as measured using thromboelastography. Blood Coagul Fibrinolysis 2007; 18: 547-553
72. Keeling D, Davidson S, Watson H. The management of heparin-induced thrombocytopenia. Br J Haematol 2006; 133: 259-269
73. Kern H, Ziemer S, Kox WJ. Bleeding after intermittent or continuous r-hirudin during CVVH. Intensive Care Med 1999; 25: 1311-1314
74. Hein OV, von Heymann C, Morgera S et al. Protracted bleeding after hirudin anticoagulation for cardiac surgery in a patient with HIT II and chronic renal failure. Artif Organs 2005; 29: 507-510
75. Frank RD, Farber H, Lanzmich R et al. In vitro studies on hirudin elimination by haemofiltration: comparison of three high-flux membranes. Nephrol Dial Transplant 2002; 17: 1957-1963
76. Hein OV, von Heymann C, Diehl T et al. Intermittent hirudin versus continuous heparin for anticoagulation in continuous renal replacement therapy. Ren Fail 2004; 26: 297-303
77. Saner F, Hertl M, Broelsch CE. Anticoagulation with hirudin for continuous veno-venous hemodialysis in liver transplantation. Acta Anaesthesiol Scand 2001; 45: 914-918
78. Selleng K, Warkentin TE, Greinacher A. Heparin-induced thrombocytopenia in intensive care patients. Crit Care Med 2007; 35: 1165-1176
79. Kiser TH, Fish DN. Evaluation of bivalirudin treatment for heparin-induced thrombocytopenia in critically ill patients with hepatic and/or renal dysfunction. Pharmacotherapy 2006; 26: 452-460
80. Lindhoff-Last E, Betz C, Bauersachs R. Use of a low-molecular-weight heparinoid (danaparoid sodium) for continuous renal replacement therapy in intensive care patients. Clin Appl Thromb Hemost 2001; 7: 300-304
81. Dang CH, Durkalski VL, Nappi JM. Evaluation of treatment with direct thrombin inhibitors in patients with heparin-induced thrombocytopenia. Pharmacotherapy 2006; 26: 461-468
82. Warkentin TE, Greinacher A, Koster A. Bivalirudin. Thromb Haemost 2008; 99: 830-839